Literature DB >> 33022763

CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.

Yini Zhu1,2, Jiling Wen1,3, Gang Huang1,3, Jackson Mittlesteadt1, Xiaofei Wen3, Xin Lu1,2,4.   

Abstract

BACKGROUND: Recent genomic profiling has identified a subtype of prostate cancer (PCa) characterized by two key genetic alterations: missense mutation of speckle-type POZ protein (SPOP) and homozygous deletion of chromodomain helicase DNA-binding protein 1 (CHD1). Mutually exclusive with E26 transformation-specific (ETS) rearrangements, this subtype displays high genomic instability. Previous studies indicate that deficient SPOP or CHD1 alone leads to feeble prostate abnormalities and each protein is involved in DNA damage response (DDR). It remains to be determined whether CHD1 and SPOP cooperate to suppress prostate tumorigenesis and DDR.
METHODS: Prostate-specific single or double knockout of Spop and Chd1 was generated with the Cre/loxP system in mice. Wild-type or mutant SPOP (F102C, F133V) overexpression and CHD1 knockdown with short hairpin RNA were created in human benign prostatic hyperplasia cell line BPH1. The levels of DNA damage and homologous recombination repair were measured by immunofluorescence staining of γH2AX and RAD51, respectively.
RESULTS: Spop/Chd1 double-knockout mice displayed prostatic intraepithelial neoplasia at both young (3 months) and old (12 months) ages and failed to generate prostate adenocarcinoma. Compared with wild-type or single-knockout mice, the double-knockout prostate harbored moderately higher proliferating cells and dramatically augmented the level of γH2AX staining, although androgen receptor-positive cells and apoptotic cells remained at a similar level. In BPH1 cell line, SPOP mutant overexpression and CHD1 silencing synergistically sensitized the cells to DNA damage by camptothecin, an inducer of double-strand breaks.
CONCLUSIONS: Our results indicate that SPOP and CHD1 can synergistically promote repair of naturally occurring or chemically induced DNA damages in prostate epithelial cells. Regarding the progression of the SPOP/CHD1 subtype of PCa, other functionally complementary drivers warrant further identification. The clinical implication is that this subtype of PCa may be particularly sensitive to poly(ADP-ribose) polymerase inhibitors or DNA-damaging agents.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  CHD1; DNA damage response; SPOP; camptothecin; genetically engineered mouse model; prostatic intraepithelial neoplasia

Mesh:

Substances:

Year:  2020        PMID: 33022763     DOI: 10.1002/pros.24080

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Detection of disease-causing mutations in prostate cancer by NGS sequencing.

Authors:  Alessandra Mangolini; Christian Rocca; Cristian Bassi; Carmelo Ippolito; Massimo Negrini; Lucio Dell'Atti; Giovanni Lanza; Roberta Gafà; Nicoletta Bianchi; Paolo Pinton; Gianluca Aguiari
Journal:  Cell Biol Int       Date:  2022-04-06       Impact factor: 4.473

Review 2.  Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes.

Authors:  Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

3.  Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.

Authors:  Navonil De Sarkar; Sayan Dasgupta; Payel Chatterjee; Ilsa Coleman; Gavin Ha; Lisa S Ang; Emily A Kohlbrenner; Sander B Frank; Talina A Nunez; Stephen J Salipante; Eva Corey; Colm Morrissey; Eliezer Van Allen; Michael T Schweizer; Michael C Haffner; Radhika Patel; Brian Hanratty; Jared M Lucas; Ruth F Dumpit; Colin C Pritchard; Robert B Montgomery; Peter S Nelson
Journal:  JCI Insight       Date:  2021-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.